TreatSMA introduces new member to the team

TreatSMA are really happy to announce Marion Main has formally joined the team and will take on the role as “TreatSMA Consultant Physio Therapist”

We are really happy to announce Marion Main has formally joined the TreatSMA Team and will take on the role as “TreatSMA Consultant Physio Therapist”.  This is great news for TreatSMA and the Community as we continue to strive forward for treatment for all, spreading awareness and information and better services.

About Marion Main

Marion has now been working in neuromuscular disorders for over 30 years, starting with Victor Dubowitz at Hammersmith Hospital. She has been qualified over 40 years and loves the rehabilitation and MSK (musculoskeletal) aspects of the work.

Marion was instrumental in designing the first SMA scale and has been involved with developing several of the scales now in common use. She has worked on standards of care and been involved in many research projects though now concentrates mostly on clinical work. She is always keen to show that physiotherapy should be manageable and fun, part of everyday life not a burden or boring chore.

Marion is committed to the idea that her team at GOSH are there to look after parents as well and never shies away from chastising those who don’t take care of themselves too…..even doing a Pilates workshop for parents.
She has a Master’s Degree in designing equipment for disability

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more